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Introduction {#ijc31854-sec-0001}
============

Worldwide there were an estimated 350,000 new cases of melanoma and 60,000 deaths from melanoma in 2015.[1](#ijc31854-bib-0001){ref-type="ref"} Exposure to ultraviolet radiation (specifically, intermittent exposure), and phenotypic characteristics such as fairer skin colour, blond or red hair and multiple naevi and freckles are established risk factors for melanoma.[2](#ijc31854-bib-0002){ref-type="ref"}, [3](#ijc31854-bib-0003){ref-type="ref"}, [4](#ijc31854-bib-0004){ref-type="ref"} There are also other putative or possible risk factors for melanoma including occupational exposure to chemicals and ionising radiation.[5](#ijc31854-bib-0005){ref-type="ref"}

Insulin‐like growth factor‐I (IGF‐I) is a polypeptide hormone that stimulates cell division and inhibits apoptosis; it is through these properties that it is thought to play a role in the development and progression of carcinogenesis.[6](#ijc31854-bib-0006){ref-type="ref"} Prospective studies have shown that higher circulating concentrations of IGF‐I are associated with a higher risk of cancers at specific sites, including the breast,[7](#ijc31854-bib-0007){ref-type="ref"} prostate[8](#ijc31854-bib-0008){ref-type="ref"} and possibly the thyroid.[9](#ijc31854-bib-0009){ref-type="ref"} Three case--control studies have examined the relationship between circulating IGF‐I concentrations and risk of melanoma, but the results were not consistent. One study found an inverse relationship between circulating IGF‐I concentration and risk of melanoma,[10](#ijc31854-bib-0010){ref-type="ref"} but two studies found an positive association.[11](#ijc31854-bib-0011){ref-type="ref"}, [12](#ijc31854-bib-0012){ref-type="ref"} The results of case--control studies may be unreliable if the development of melanoma affects circulating IGF‐I concentrations, or if bias was introduced in the selection of controls.[13](#ijc31854-bib-0013){ref-type="ref"} Given this uncertainty, we examined the association between circulating IGF‐I concentrations measured in adulthood and the subsequent risk of melanoma in a case--control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.

Methods {#ijc31854-sec-0002}
=======

Study population {#ijc31854-sec-0003}
----------------

The study design, including the recruitment, blood collection and follow‐up procedures of EPIC has been described previously.[14](#ijc31854-bib-0014){ref-type="ref"} Briefly, between 1992 and 2000 approximately 520,000 participants, mostly aged between 35 and 70 years, were recruited from 23 centres in 10 European countries (Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden and the United Kingdom). Participants provided information on sociodemographic characteristics, dietary intakes and lifestyle factors. The study was approved by the International Agency for Research on Cancer Ethics Committee and local ethics committees in the participating countries. All participants gave written informed consent.

Selection of cases and controls {#ijc31854-sec-0004}
-------------------------------

In most centres, follow‐up for cancer incidence and mortality was conducted *via* record linkage with regional and national registries. In France, Germany and Greece, follow‐up was by a combination of methods, including health insurance records, cancer and pathology registries and active follow‐up through study subjects and their next‐of‐kin.[15](#ijc31854-bib-0015){ref-type="ref"}

Cases were participants who were diagnosed with incident invasive melanoma of the skin (WHO international classification of diseases‐oncology third edition (ICD‐O‐3) Codes 8,720--8,790, with fifth digit behaviour Code 3 signifying invasive malignancies) during follow‐up, and who had donated a blood sample and had not been diagnosed with cancer (except for nonmelanoma skin cancer) at baseline, and had not been diagnosed with other tumours (except nonmelanoma skin cancer) before the melanoma diagnosis. Superficial spreading melanomas were defined as tumours with ICD‐O‐3 morphology code 8743/3, and nodular melanomas as those with ICD‐O‐3 morphology code 8721/3. Melanomas of the head and neck were tumours with international classification of diseases 10th edition (ICD‐10) site codes C44.0‐C44.4, melanomas of the trunk were those with ICD‐10 site code C44.5, melanomas of the upper limbs were those with ICD‐10 site code C44.6, and melanomas of the lower limbs were those with ICD‐10 site code C44.7. Participants were eligible for selection as a control if they had provided a blood sample at baseline, and were alive and without a cancer diagnosis (other than nonmelanoma skin cancer) at the time of the diagnosis of the index case. Randomly chosen controls were matched (1:1) to each case using incidence density sampling.[16](#ijc31854-bib-0016){ref-type="ref"} The matching criteria were: study centre, gender, age at blood collection (± 1 year), and date (± 3 months), time of day (± 3 hr), and fasting status (\< 3 hr, 3 to 6 hr, \> 6 hr) at blood collection. The present study includes 1,221 cases and 1,221 controls (523 male cases and controls; 698 female cases and controls).

Laboratory measurements {#ijc31854-sec-0005}
-----------------------

Approximately 75% of participants provided a blood sample at recruitment.[15](#ijc31854-bib-0015){ref-type="ref"} In most centres whole blood was transported to a local laboratory, processed within 24 hr, and transported to be stored centrally in liquid nitrogen at −196°C at the International Agency for Research on Cancer. In Denmark, all blood samples were stored locally in nitrogen vapour at −150°C, and in Sweden all blood samples were stored in electric freezers at −70°C. In the Oxford cohort, samples were sent at ambient temperature to a central laboratory in Norfolk, UK with a mean transit time of 1.5 days.

IGF‐I concentration was measured in serum samples, except for the participants from Norway and Umeå (Sweden), for which citrated plasma and EDTA plasma samples were used, respectively. IGF‐I concentration was measured in the Cancer Epidemiology Unit (Oxford, United Kingdom) using the automated IDS‐iSYS immunoassay system from Immunodiagnostic Systems Ltd (Tyne & Wear, United Kingdom).[17](#ijc31854-bib-0017){ref-type="ref"} Laboratory personnel were blind to the case--control status of the samples and each case--control set was analysed in the same batch, together with duplicate quality control samples. The intra‐ and inter‐assay coefficients of variation were 3.9% and 4.7% at an overall mean concentration of 14.2 nmol/l.

Statistical analyses {#ijc31854-sec-0006}
--------------------

All statistical analyses were run using Stata version 14.1 (Stata Corp, College Station, TX). Participant characteristics were compared between cases and controls, for men and women separately, using the paired‐sample *t* test for continuous variables and the chi‐square test for categorical variables.

IGF‐I concentration was logarithmically transformed (using the natural log transformation) to approximate a normal distribution. Among controls only, geometric mean serum IGF‐I concentrations by participant characteristics were investigated using analysis of variance (ANOVA), adjusted for batch, age at blood collection (as a continuous variable), gender, country and alcohol intake. Tests for linear trends across categories were performed by scoring categories with consecutive integers.

Odds ratios (ORs) and 95% confidence intervals (CIs) for melanoma by quintiles of gender‐specific serum IGF‐I concentration at baseline (based on the gender‐specific distributions in the controls) were estimated using conditional logistic regression, conditioned on the matching variables. In the multivariable model, to allow for finer adjustment for age, the model was adjusted for age at blood collection (in months, as a continuous variable), as well as education (primary/none, secondary, degree), height (gender‐specific quartiles), BMI (gender‐specific quartiles), smoking status (never, former, current), alcohol intake (\<1, 1--7, 8--19, 20--39, \>40 g/d), marital status (married/cohabiting, unmarried/not cohabiting), physical activity (inactive, moderately inactive, moderately active, active[18](#ijc31854-bib-0018){ref-type="ref"}), and in women only, use of menopausal hormone therapy (current, not current). For all covariates, any missing values were assigned to a separate category. The odds of melanoma associated with a doubling of IGF‐I concentration were investigated as described above but using the logarithm to the base 2 of serum IGF‐I concentration.

Using conditional logistic regression, conditioning on the matching factors and adjusting for the covariates listed above (where relevant), we also examined the association between IGF‐I and melanoma subdivided by major participant characteristics: gender, age at blood collection (\< 55 years, ≥ 55 years), BMI (\< 25 kg/m^2^, ≥ 25 kg/m^2^), height (gender‐specific medians: \< 176 cm (men) or \< 163 cm (women), ≥ 176 cm (men) or ≥ 163 cm (women)), and age at case diagnosis (\< 60 years, ≥ 60 years). In addition, to investigate the possibility of reverse causality we examined the association between IGF‐I and melanoma subdivided by time between blood collection and diagnosis (\< 4 years, ≥ 4 years). Finally, to explore whether IGF‐I may be differentially associated with subtypes of melanoma, we examined the association between IGF‐I and melanoma risk in categories of anatomical site (head and neck, trunk, upper limbs, and lower limbs) and histological subtype (superficial spreading and nodular melanoma) of the tumour. For these analyses, controls were assigned to the same category as their matched case. For the BMI subgroup analysis, participants were only included if both the case and matched control had a BMI \<25 kg/m^2^, or if both case and matched control had a BMI ≥ 25 kg/m^2^, with similar rules for the analyses subdivided by height and age at blood collection. Tests for heterogeneity of risk between subgroups were performed using the likelihood ratio test, comparing models with and without the interaction term between the logarithm of circulating IGF‐I concentration and the variable of interest.

All statistical tests were two‐sided, and *p* \< 0.05 was considered statistically significant.

Results {#ijc31854-sec-0007}
=======

Among men, cases were slightly taller, were more likely to have a university degree, and less likely to be current smokers, compared to the controls. Among women, cases were also slightly taller, but were otherwise similar to controls with regards to the characteristics listed in Table [1](#ijc31854-tbl-0001){ref-type="table"}. Among the cases, the mean time from blood collection to diagnosis was 6.5 years.

###### 

Characteristics of the melanoma cases and controls

                                                Controls            Cases               *p* ~difference~ [1](#ijc31854-note-0001){ref-type="fn"}   
  --------------------------------------------- ------------------- ------------------- ---------------------------------------------------------- --
                                                Men                                                                                                
  n                                             523                 523                                                                            
  Mean (SD) age at blood collection (years)     55.1 (8.1)          55.1 (8.1)          \*                                                         
  Mean (SD) height (cm)                         175.3 (6.9)         176.5 (7.0)         0.004                                                      
  Mean (SD) BMI (kg/m^2^)                       26.2 (3.5)          26.4 (3.3)          0.322                                                      
  Education                                                                                                                                        
  Primary/none                                  35.7 (183)          29.7 (151)          0.048                                                      
  Secondary                                     38.0 (195)          37.8 (192)                                                                     
  Degree                                        26.3 (135)          32.5 (165)                                                                     
  Alcohol intake (g/day)                                                                                                                           
  \< 1                                          9.2 (48)            8.7 (45)            0.718                                                      
  1--7                                          26.8 (140)          24.0 (125)                                                                     
  8--19                                         27.9 (146)          29.0 (151)                                                                     
  20--39                                        21.8 (114)          21.4 (111)                                                                     
  ≥ 40                                          14.3 (75)           16.9 (88)                                                                      
  Smoking status                                                                                                                                   
  Never                                         34.2 (177)          37.0 (190)          0.023                                                      
  Former                                        37.1 (192)          41.6 (214)                                                                     
  Current                                       28.8 (149)          21.4 (110)                                                                     
  Physical activity                                                                                                                                
  Inactive                                      20.3 (103)          15.6 (79)           0.259                                                      
  Moderately inactive                           33.1 (168)          34.7 (176)                                                                     
  Moderately active                             22.1 (112)          24.4 (124)                                                                     
  Active                                        24.6 (125)          25.4 (129)                                                                     
  Mean (95% CI) IGF‐I concentrations (nmol/L)   18.2 (17.7--18.6)   18.2 (17.8--18.6)   0.912                                                      
                                                Women                                                                                              
  n                                             698                 698                                                                            
  Mean (SD) age at blood collection (years)     53.9 (9.0)          53.9 (9.0)          \*                                                         
  Mean (SD) height (cm)                         162.2 (6.6)         163.0 (6.4)         0.016                                                      
  Mean (SD) BMI (kg/m^2^)                       25.3 (4.3)          25.3 (4.6)          0.948                                                      
  Education                                                                                                                                        
  Primary/none                                  32.3 (218)          30.5 (206)          0.604                                                      
  Secondary                                     49.9 (337)          49.8 (336)                                                                     
  Degree                                        17.8 (120)          19.7 (133)                                                                     
  Alcohol intake (g/day)                                                                                                                           
  \< 1                                          28.8 (201)          29.7 (207)          0.972                                                      
  1--7                                          35.7 (249)          36.5 (255)                                                                     
  8--19                                         24.1 (168)          23.2 (162)                                                                     
  20--39                                        8.9 (62)            8.3 (58)                                                                       
  ≥ 40                                          2.6 (18)            2.3 (16)                                                                       
  Smoking status                                                                                                                                   
  Never                                         53.3 (369)          52.6 (361)          0.890                                                      
  Former                                        26.8 (186)          26.5 (182)                                                                     
  Current                                       19.9 (138)          21.0 (144)                                                                     
  Physical activity                                                                                                                                
  Inactive                                      23.9 (158)          23.1 (152)          0.801                                                      
  Moderately inactive                           33.7 (223)          36.4 (240)                                                                     
  Moderately active                             22.1 (146)          21.7 (143)                                                                     
  Active                                        20.3 (134)          18.8 (124)                                                                     
  Parity                                                                                                                                           
  Nulliparous                                   13.5 (88)           12.7 (83)           0.480                                                      
  1                                             18.0 (117)          14.8 (97)                                                                      
  2                                             43.8 (285)          46.1 (302)                                                                     
  3                                             16.9 (110)          18.9 (124)                                                                     
  4 or more                                     7.8 (51)            7.5 (49)                                                                       
  Oral contraceptive use                                                                                                                           
  Never                                         42.6 (289)          42.1 (287)          0.876                                                      
  Ever                                          57.4 (390)          57.9 (394)                                                                     
  Menopausal hormone therapy use                                                                                                                   
  Not current                                   81.9 (546)          80.1 (534)          0.403                                                      
  Current                                       18.1 (121)          19.9 (133)                                                                     
  Mean (95% CI) IGF‐I concentrations (nmol/L)   17.4 (17.0--17.7)   17.5 (17.1--17.9)   0.593                                                      

Values are % (n) unless otherwise stated.

The paired‐sample *t* test was used for continuous variables and the chi‐square test was used for categorical variables. *\*p* values were not calculated for matching factors.

Among the controls, geometric mean IGF‐I concentrations were significantly lower in women, in those who were older at blood collection, and in those who drank the most alcohol (Table [2](#ijc31854-tbl-0002){ref-type="table"}). Among women, current menopausal hormone therapy users had lower mean IGF‐I concentrations. The lowest concentrations of IGF‐I were in the first and fourth quartiles of BMI and the highest concentrations were in the second and third quartiles. Circulating IGF‐I concentrations differed by country; participants from the Netherlands had the highest mean IGF‐I concentrations.

###### 

Adjusted geometric mean IGF‐I concentrations (nmol/L) by participant characteristics in 1221 controls

  Characteristic                                                             n    Geometric mean (95% CI)  P~difference~ [1](#ijc31854-note-0003){ref-type="fn"}
  ------------------------------------------------------------------------ ----- ------------------------- -------------------------------------------------------
  Gender[2](#ijc31854-note-0004){ref-type="fn"}                                                            
  Men                                                                       523      18.2 (17.8--18.6)     0.002
  Women                                                                     698      17.3 (17.0--17.7)     
  Age at blood collection (years)[3](#ijc31854-note-0005){ref-type="fn"}                                   
  \<50                                                                      292      20.0 (19.3--20.6)     \<0.001
  50--54                                                                    302      17.9 (17.4--18.5)     
  55--59                                                                    282      16.9 (16.4--17.4)     
  60--64                                                                    207      16.8 (16.2--17.5)     
  ≥ 65                                                                      138      15.9 (15.2--16.6)     
  Country[4](#ijc31854-note-0006){ref-type="fn"}                                                           
  Denmark                                                                   258      17.3 (16.6--18.1)     0.004
  France                                                                    49       18.5 (17.1--20.1)     
  Germany                                                                   146      17.0 (15.9--18.1)     
  Greece                                                                    18       16.5 (14.5--18.9)     
  Italy                                                                     110      18.3 (17.3--19.4)     
  Netherlands                                                               109      19.5 (18.2--20.9)     
  Norway                                                                    27       14.4 (11.8--17.5)     
  Spain                                                                     70       17.5 (16.3--18.7)     
  Sweden                                                                    272      17.6 (16.5--18.8)     
  UK                                                                        162      18.1 (17.2--19.1)     
  Education                                                                                                
  Primary/none                                                              401      17.3 (16.9--17.8)     0.118
  Secondary school                                                          532      17.8 (17.4--18.2)     
  Degree                                                                    255      18.1 (17.5--18.8)     
  Height (quartiles)[5](#ijc31854-note-0007){ref-type="fn"}                                                
  Lowest quartile                                                           336      17.4 (16.9--17.9)     0.131
  2                                                                         347      17.5 (17.0--18.0)     
  3                                                                         280      18.3 (17.7--18.9)     
  Highest quartile                                                          258      17.8 (17.2--18.4)     
  BMI (kg/m^2^)[6](#ijc31854-note-0008){ref-type="fn"}                                                     
  Lowest quartile                                                           302      17.4 (16.8--17.9)     0.036
  2                                                                         315      18.2 (17.6--18.7)     
  3                                                                         306      18.0 (17.5--18.6)     
  Highest quartile                                                          298      17.3 (16.7--17.8)     
  Alcohol intake (g/day)[7](#ijc31854-note-0009){ref-type="fn"}                                            
  \<1                                                                       249      18.3 (17.6--18.9)     0.023
  1--7                                                                      389      18.0 (17.5--18.5)     
  8--19                                                                     314      17.6 (17.1--18.2)     
  20--39                                                                    176      17.2 (16.5--17.9)     
  ≥ 40                                                                      93       16.4 (15.5--17.4)     
  Smoking status                                                                                           
  Never                                                                     546      17.5 (17.1--17.9)     0.440
  Former                                                                    378      17.9 (17.4--18.4)     
  Current                                                                   287      17.8 (17.2--18.3)     
  Physical activity                                                                                        
  Inactive                                                                  261      17.8 (17.2--18.4)     0.546
  Moderately inactive                                                       399      17.7 (17.2--18.2)     
  Moderately active                                                         271      17.8 (17.2--18.4)     
  Active                                                                    263      17.3 (16.7--17.9)     
  Marital status                                                                                           
  Married/co‐habiting                                                       677      17.8 (17.5--18.2)     0.719
  Unmarried/not co‐habiting                                                 194      17.7 (17.0--18.4)     
  Parity                                                                                                   
  Nulliparous                                                               88       17.9 (16.9--18.9)     
  One                                                                       117      17.5 (16.7--18.4)     0.062
  Two                                                                       286      16.9 (16.4--17.4)     
  Three                                                                     110      17.7 (16.9--18.6)     
  Four or more                                                              51       16.0 (14.9--17.2)     
  Oral contraceptive use                                                                                   
  Never                                                                     289      17.5 (17.0--18.1)     0.351
  Ever                                                                      390      17.2 (16.7--17.6)     
  Menopausal hormone therapy use                                                                           
  Not current                                                               546      17.5 (17.2--17.9)     0.011
  Current                                                                   121      16.3 (15.6--17.2)     

Adjusted for batch, age at blood collection, gender, country and alcohol intake unless otherwise stated.

*p* values refer to tests of difference between the logarithm of IGF‐I concentration in the separate categories (excluding unknowns) calculated by ANOVA.

Adjusted for batch and age at blood collection.

Adjusted for batch and gender.

Adjusted for batch, age at blood collection and gender.

The quartile ranges for height for men were: 150.00--171.00 cm (Quartile 1), 171.20--176.00 cm (Quartile 2), 176.13--181.00 cm (Quartile 3), and 181.30--195.00 cm (Quartile 4) and for women were: 142.00--158.36 cm (Quartile 1), 158.40--163.00 cm (Quartile 2), 163.08--167.00 cm(Quartile 3) and 167.10--184.00 cm (Quartile 4).

The quartile ranges for BMI for men were: 16.58--23.97 kg/m^2^ (Quartile 1), 24.06--26.01 kg/m^2^ (Quartile 2), 26.02--28.25 kg/m^2^ (Quartile 3), and 28.29--39.58 kg/m^2^ (Quartile 4) and for women were: 15.15--22.19 kg/m^2^ (Quartile 1), 22.22--24.45 kg/m^2^ (Quartile 2), 24.50--27.60 kg/m^2^(Quartile 3) and 27.62--43.19 kg/m^2^ (Quartile 4).

Adjusted for batch, age at blood collection, gender and country.

There was no significant association between serum IGF‐I concentrations and the risk of melanoma in either the basic model, or in the fully adjusted model, further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity, and use of menopausal hormone therapy. In the fully adjusted model, the OR for a doubling in IGF‐I concentration was 1.04 (95% CI: 0.84--1.28, *p* ~trend~ = 0.736) (Table [3](#ijc31854-tbl-0003){ref-type="table"}). When we examined the associations in prespecified subgroups, we found no significant differences in associations by gender, age at blood collection, BMI, height, age at diagnosis, or years between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (*p* ~heterogeneity~ ≥ 0.078, for all subdivisions) (Table [4](#ijc31854-tbl-0004){ref-type="table"}).

###### 

Odds ratios for melanoma by gender‐specific fifths of circulating IGF‐I concentration

                                                                                       Gender‐specific fifth of IGF‐I concentration[1](#ijc31854-note-0012){ref-type="fn"}   Doubling of concentration                                                                                   
  ------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------- --------------------------- ------------------- ------------------- ------------------- ------------------- ----------
                                                                                       Lowest                                                                                2                           3                   4                   Highest             OR (95% CI)         P~trend~
                                                                n~cases~/n~controls~   259/245                                                                               229/245                     225/243             267/245             241/243             1221/1221           
  Basic model[2](#ijc31854-note-0013){ref-type="fn"}                                   1.00 (ref)                                                                            0.89 (0.69--1.14)           0.88 (0.69--1.13)   1.03 (0.80--1.32)   0.95 (0.73--1.23)   1.05 (0.86--1.29)   0.629
  Fully adjusted model[3](#ijc31854-note-0014){ref-type="fn"}                          1.00 (ref)                                                                            0.88 (0.68--1.14)           0.87 (0.67--1.13)   1.01 (0.78--1.31)   0.93 (0.71--1.22)   1.04 (0.84--1.28)   0.736

Abbreviation: OR, odds ratio.

Case and control participants were matched on study centre, sex, age at blood collection (± 1 year) and date (± 3 months), time of day (± 3 hr) and fasting status (\< 3 hr, 3 to 6 hr, \> 6 hr) at blood collection.

The category ranges for IGF‐I concentration for men were: 12.71--14.59 nmol/l (lowest fifth), 16.16--17.24 nmol/l, 18.47--19.49 nmol/l, 21.10--23.06 kg/m^2^ and 25.49--53.08 nmol/l (highest fifth) and for women were: 12.11--13.97 nmol/l (lowest fifth), 15.09--16.30 nmol/l, 17.36--18.68 nmol/l, and 20.04--22.19 nmol/l and 25.28--50.23 nmol/l (highest fifth).

ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above).

ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above) and adjusted for age at blood collection (continuous), education (primary/none, secondary, degree, unknown), height (sex‐specific quartiles), BMI (sex‐specific quartiles), smoking (never, former, current, unknown), alcohol intake (\<1 g, 1--7 g, 8--19 g, 20--39 g, ≥ 40 g, unknown), marital status (married/cohabiting, unmarried/not cohabiting, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown) and current use of menopausal hormone therapy (no, yes, unknown or male).

###### 

Relationship between circulating IGF‐I concentration and risk of melanoma, subdivided by participant and tumour characteristics

                                                                    n~cases~/n~controls~   OR (95% CI) for a doubling in IGF‐I concentration[1](#ijc31854-note-0016){ref-type="fn"}   P~trend~  P~heterogeneity~
  ---------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------ ---------- ------------------
  Gender                                                                                                                                                                                        
  Men                                                                     523/523                                             1.00 (0.71--1.41)                                        0.983    0.707
  Women                                                                   698/698                                             1.04 (0.79--1.38)                                        0.760    
  Age at blood collection[2](#ijc31854-note-0017){ref-type="fn"}                                                                                                                                
  \< 55 years                                                             587/587                                             1.15 (0.82--1.60)                                        0.423    0.335
  ≥ 55 years                                                              623/623                                             0.91 (0.68--1.22)                                        0.523    
  BMI[3](#ijc31854-note-0018){ref-type="fn"}                                                                                                                                                    
  \< 25 kg/m^2^                                                           315/315                                             1.56 (0.99--2.45)                                        0.051    0131
  ≥ 25 kg/m^2^                                                            368/368                                             0.88 (0.60--1.28)                                        0.496    
  Height[4](#ijc31854-note-0019){ref-type="fn"}                                                                                                                                                 
  \< 176 cm (men) or \< 163 cm (women)                                    324/324                                             0.97 (0.65--1.45)                                        0.866    0.935
  ≥ 176 cm (men) or ≥ 163 cm (women)                                      347/347                                             0.94 (0.62--1.43)                                        0.771    
  Age at diagnosis                                                                                                                                                                              
  \< 60 years                                                             513/513                                             1.03 (0.72--1.47)                                        0.878    0.865
  ≥ 60 years                                                              708/708                                             0.98 (0.74--1.29)                                        0.885    
  Time between blood collection and diagnosis                                                                                                                                                   
  \< 4 years                                                              361/361                                             0.79 (0.53--1.18)                                        0.246    0.078
  ≥ 4 years                                                               860/860                                             1.18 (0.91--1.52)                                        0.212    
  Tumour characteristics                                                                                                                                                                        
  Anatomical site                                                                                                                                                                               
  Head and neck                                                           125/125                                             0.47 (0.18--1.22)                                        0.116    0.468
  Trunk                                                                   400/400                                             1.27 (0.87--1.87)                                        0.217    
  Upper limbs                                                             244/244                                             0.89 (0.54--1.48)                                        0.651    
  Lower limbs                                                             332/332                                             1.22 (0.80--1.85)                                        0.354    
  Histological subtype                                                                                                                                                                          
  Superficial spreading                                                   537/537                                             1.01 (0.73--1.40)                                        0.942    0.249
  Nodular melanoma                                                        114/114                                             0.57 (0.25--1.29)                                        0.175    

Case and control participants were matched on study centre, gender, age at blood collection (± 1 year) and date (± 3 months), time of day (± 3 hr), and fasting status (\< 3 hr, 3 to 6 hr, \> 6 hr) at blood collection.

ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above) and adjusted for age at blood collection (continuous), height (gender‐specific quartiles), BMI (gender‐specific quartiles), education (primary/none, secondary, degree, unknown), smoking (never, former, current, unknown), alcohol intake (\<1 g, 1--7 g, 8--19 g, 20--39 g, ≥40 g, unknown), marital status (married/cohabiting, unmarried/not cohabiting, unknown), physical activity (inactive, moderately inactive, moderately active, unknown), and current use of menopausal hormone therapy where appropriate.

Participants were included in the age at blood collection subgroup analysis if both the case and the matched control were aged \<55 years, or if both the case and the matched control were aged ≥55 years.

Participants were included in the BMI subgroup analysis if both the case and the matched control had a BMI \<25 kg/m^2^, or if both the case and the matched control had a BMI ≥25 kg/m^2^.

Participants were included in the height subgroup analysis if both the case and the matched control had height \< 176 cm (men) or \< 163 cm (women), or if both the case and the matched control had height ≥176 cm (men) or ≥ 163 cm (women).

Discussion {#ijc31854-sec-0008}
==========

To the best of our knowledge, this is the first prospective study to examine circulating concentration of IGF‐I measured in adulthood in relation to the risk of melanoma. We found no association overall, or for specific anatomical sites or histological subtypes of melanoma. Furthermore, we found no evidence of heterogeneity in the association between circulating IGF‐I concentrations and risk of melanoma by sex, age at blood collection, BMI, height, age at diagnosis, or time between blood collection and diagnosis.

Three small case--control studies have examined circulating IGF‐I concentrations and risk of melanoma, but the findings were inconsistent.[10](#ijc31854-bib-0010){ref-type="ref"}, [11](#ijc31854-bib-0011){ref-type="ref"}, [12](#ijc31854-bib-0012){ref-type="ref"} The reason for the inconsistency in the results of these case--control studies is unclear, but the selection of controls in a case--control study can bias the association between exposure and disease.[13](#ijc31854-bib-0013){ref-type="ref"} In addition, the results of case--control studies may be influenced by reverse causation bias if the presence of disease affects circulating IGF‐I concentrations.

Laboratory work has indicated that the IGF‐I axis may play a role in melanoma progression; specifically, studies have reported that IGF‐I enhances survival and migration of melanoma cells *in vitro*.[19](#ijc31854-bib-0019){ref-type="ref"}, [20](#ijc31854-bib-0020){ref-type="ref"} However, the present large prospective study did not find any relation between circulating IGF‐I concentrations and the risk of developing melanoma.

The strengths of our study include the large sample size, and the nested‐case control design, which allowed for the collection of blood samples before diagnosis of melanoma. A limitation of our study is that we did not have information on some of the major risk factors for melanoma---sun exposure, skin phototype, or family history of melanoma[2](#ijc31854-bib-0002){ref-type="ref"}, [3](#ijc31854-bib-0003){ref-type="ref"}, [4](#ijc31854-bib-0004){ref-type="ref"}--and therefore we were unable to adjust for these factors in our analysis. However, these factors would only distort the association of IGF‐I with melanoma if they were also associated with circulating IGF‐I concentrations. In a previous case--control study, adjusting for number of lifetime blistering sunburns, ability to tan and hair colour did not appreciably alter the association between IGF‐I and melanoma risk.[11](#ijc31854-bib-0011){ref-type="ref"} In addition, in our study we used a single measure of circulating IGF‐I concentration, but previous work has shown good reproducibility of circulating IGF‐I concentrations over three (intra‐class correlation (ICC) = 0.86),[21](#ijc31854-bib-0021){ref-type="ref"} and five (ICC = 0.71) years.[22](#ijc31854-bib-0022){ref-type="ref"} Finally, more than 90% of circulating IGF‐I is bound to IGF binding protein (IGFBP)‐3[23](#ijc31854-bib-0023){ref-type="ref"} and we did not measure IGFBPs in our study. IGFBPs may affect the bioavailability and signalling of IGF‐I, but the regulation of IGF‐I action by the IGFBPs is complex and not fully characterised.[6](#ijc31854-bib-0006){ref-type="ref"} Prospective studies of breast[7](#ijc31854-bib-0007){ref-type="ref"} and prostate cancer,[8](#ijc31854-bib-0008){ref-type="ref"} have found positive associations with circulating IGF‐I concentrations and cancer risk, that were not changed after adjustment for the predominant binding protein, IGFBP‐3.

In conclusion, in this large prospective study, which included a total of 1,221 cases of incident melanoma, we did not find any evidence that circulating IGF‐I concentration measured in adulthood was associated with the risk of melanoma.
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